The 8 most recent market catalysts affecting $CRMD, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 23, 2026
Corporate Catalyst
Neutral
Impact 65
Oppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15
Oppenheimer's initiation of coverage on Cormedix with an Outperform rating and a $15 price target is a positive development for the company. Analyst coverage can increase visibilit…
Sep 8, 2026
Corporate Catalyst
Neutral
Impact 55
Carlsmed Announces Promotion Of Jeff Bertolini To COO, Effective Immediately
The promotion of a COO is a positive internal development for Carlmed, indicating a focus on operational excellence and potentially smoother execution of strategic initiatives. Whi…
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14
RBC Capital analyst Leonid Timashev has maintained an Outperform rating on Cormedix and raised the price target from $13 to $14. This action signals continued confidence from a pro…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 85
CorMedix Stock Jumps on Strong DefenCath Sales
CorMedix Inc. announced impressive second-quarter results, with adjusted earnings and revenue surpassing consensus estimates. The significant driver of this performance was the str…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 75
CorMedix shares are trading higher after the company reported better-than-expected Q2 financial results.
This headline represents a significant corporate catalyst for CorMedix. Better-than-expected financial results directly impact investor perception of a company's health and future …
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 75
Cormedix Q2 EPS $0.29 Beats $0.25 Estimate, Sales $101.931M Beat $95.621M Estimate
This headline is a significant corporate catalyst for Cormedix (CRMD). Beating both EPS and sales estimates suggests strong underlying business performance, potentially driven by s…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 55
Cormedix Affirms FY2026 Sales Guidance of $325.000M-$345.000M vs $334.089M Est
Cormedix (CRMD) filed an 8-K to affirm its fiscal year 2026 sales guidance, keeping the range at $325 million to $345 million. This filing essentially communicates that the company…
Aug 7, 2026
Corporate Catalyst
Neutral
Impact 55
U.S. District Court Granted Preliminary Approval Of CorMedix Derivative Settlement On July 24; Final Hearing Set For September 23
CorMedix announced that a U.S. District Court has granted preliminary approval for a derivative settlement. This is a positive step towards resolving a legal issue that likely invo…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.